Comprehensive analysis and experimental verification of the mechanism of action of T cell-mediated tumor-killing related genes in Colon adenocarcinoma

被引:3
作者
Chen, Jing [1 ]
Wang, Zhengfang [1 ]
Zhu, Qin [2 ]
Ren, Shiqi [3 ]
Xu, Yanhua [1 ]
Wang, Guangzhou [1 ]
Zhou, Lin [1 ]
机构
[1] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Clin Med Coll, Dept Med Lab, Yangzhou 225009, Jiangsu, Peoples R China
[2] Dalian Third Peoples Hosp, Dept Trauma Hand Surg, Dalian 116000, Peoples R China
[3] Nantong Univ, Med Sch, Affiliated Hosp, Dept Hand Surg, Nantong 226001, Peoples R China
关键词
Colon adenocarcinoma; Gene signature; T cell-mediated tumor killing; Single cell data; COLORECTAL-CANCER; MAST-CELLS; EXPRESSION; RECEPTOR; HOXC6; CHEMOKINE;
D O I
10.1016/j.tranon.2024.101918
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Colorectal cancer (CRC) is a prevalent malignancy of the digestive tract. A new prognostic scoring model for colon adenocarcinoma (COAD) is developed in this study based on the genes involved in tumor cellmediated killing of T cells (GSTTKs), accurately stratifying COAD patients, thus improving the current status of personalized treatment. Method: The GEO and TCGA databases served as the sources of the data for the COAD cohort. This study identified GSTTKs-related genes in COAD through single-factor Cox analysis. These genes were used to categorize COAD patients into several subtypes via unsupervised clustering analysis. The biological pathways and tumor microenvironments of different subgroups were compared. We performed intersection analysis between different subtypes to obtain intersection genes. Single-factor Cox regression analysis and Lasso-Cox analysis were conducted to establish clinical prognostic models. Two methods are used to assess the accuracy of model predictions: ROC and Kaplan-Meier analysis. Next, the prediction model was further validated in the validation cohort. Differential immune cell infiltration between various risk categories was identified via single sample gene set enrichment analysis (ssGSEA). The COAD model's gene expression was validated via single-cell data analysis and experiments. Result: We established two distinct GSTTKs-related subtypes. Biological processes and immune cell tumor invasion differed significantly between various subtypes. Clinical prognostic models were created using five GSTTKs-related genes. The model's risk score independently served as a prognostic factor. COAD patients were classified as low- or high-risk depending on their risk scores. Patients in the low-risk category recorded a greater chance of surviving. The outcomes from the validation cohort match those from the training set. Risk scores and several tumor-infiltrating immune cells were strongly correlated, according to ssGSEA. Single-cell data illustrated that the model's genes were linked to several immune cells. The experimental results demonstrated a significant increase in the expression of HOXC6 in colon cancer tissue. Conclusion: Our research findings established a new gene signature for COAD. This gene signature helps to accurately stratify the risk of COAD patients and improve the current status of individualized care.
引用
收藏
页数:16
相关论文
共 47 条
[1]   HOXC6 Is Transcriptionally Regulated via Coordination of MLL Histone Methylase and Estrogen Receptor in an Estrogen Environment [J].
Ansari, Khairul I. ;
Hussain, Imran ;
Shrestha, Bishakha ;
Kasiri, Sahba ;
Mandal, Subhrangsu S. .
JOURNAL OF MOLECULAR BIOLOGY, 2011, 411 (02) :334-349
[2]   Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy [J].
Bao, Xuanwen ;
Zhang, Hangyu ;
Wu, Wei ;
Cheng, Shaobing ;
Dai, Xiaomeng ;
Zhu, Xudong ;
Fu, Qihan ;
Tong, Zhou ;
Liu, Lulu ;
Zheng, Yi ;
Zhao, Peng ;
Fang, Weijia ;
Liu, Fanglong .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[3]   Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and benign and malignant lymphoid tissue [J].
Bijl, J ;
vanOostveen, JW ;
Kreike, M ;
Rieger, E ;
vanderRaaijHelmer, LMH ;
Walboomers, JMM ;
Corte, G ;
Boncinelli, E ;
vandenBrule, AJC ;
Meijer, CJLM .
BLOOD, 1996, 87 (05) :1737-1745
[4]   Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review [J].
Biller, Leah H. ;
Schrag, Deborah .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (07) :669-685
[5]  
Bodey B, 2000, ANTICANCER RES, V20, P2711
[6]   LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer [J].
Carpenter, Katherine J. ;
Valfort, Aurore-Cecile ;
Steinauer, Nick ;
Chatterjee, Arindam ;
Abuirqeba, Suomia ;
Majidi, Shabnam ;
Sengupta, Monideepa ;
Di Paolo, Richard J. ;
Shornick, Laurie P. ;
Zhang, Jinsong ;
Flaveny, Colin A. .
SCIENTIFIC REPORTS, 2019, 9 (1)
[7]   HOMEOBOX GENES - POTENTIAL CANDIDATES FOR THE TRANSCRIPTIONAL CONTROL OF THE TRANSFORMED AND INVASIVE PHENOTYPE [J].
CASTRONOVO, V ;
KUSAKA, M ;
CHARIOT, A ;
GIELEN, J ;
SOBEL, M .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (01) :137-143
[8]   Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity [J].
Chow, Andrew ;
Schad, Sara ;
Green, Michael D. ;
Hellmann, Matthew D. ;
Allaj, Viola ;
Ceglia, Nicholas ;
Zago, Giulia ;
Shah, Nisargbhai S. ;
Sharma, Sai Kiran ;
Mattar, Marissa ;
Chan, Joseph ;
Rizvi, Hira ;
Zhong, Hong ;
Liu, Cailian ;
Bykov, Yonina ;
Zamarin, Dmitriy ;
Shi, Hongyu ;
Budhu, Sadna ;
Wohlhieter, Corrin ;
Uddin, Fathema ;
Gupta, Aditi ;
Khodos, Inna ;
Waninger, Jessica J. ;
Qin, Angel ;
Markowitz, Geoffrey J. ;
Mittal, Vivek ;
Balachandran, Vinod ;
Durham, Jennifer N. ;
Le, Dung T. ;
Zou, Weiping ;
Shah, Sohrab P. ;
McPherson, Andrew ;
Panageas, Katherine ;
Lewis, Jason S. ;
Perry, Justin S. A. ;
de Stanchina, Elisa ;
Sen, Triparna ;
Poirier, John T. ;
Wolchok, Jedd D. ;
Rudin, Charles M. ;
Merghoub, Taha .
CANCER CELL, 2021, 39 (07) :973-+
[9]   Colorectal cancer [J].
Dekker, Evelien ;
Tanis, Pieter J. ;
Vleugels, Jasper L. A. ;
Kasi, Pashtoon M. ;
Wallace, Michael B. .
LANCET, 2019, 394 (10207) :1467-1480
[10]   Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy [J].
Dunne, Philip D. ;
McArt, Darragh G. ;
O'Reilly, Paul G. ;
Coleman, Helen G. ;
Allen, Wendy L. ;
Loughrey, Maurice ;
Van Schaeybroeck, Sandra ;
McDade, Simon ;
Salto-Tellez, Manuel ;
Longley, Daniel B. ;
Lawler, Mark ;
Johnston, Patrick G. .
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (07) :582-591